Chronic Administration of Melatonin: Physiological and Clinical Considerations

Background: Exogenous melatonin is commonly used to treat insomnia, other sleep problems, and numerous medical illnesses, including Alzheimer's disease, autism spectrum disorder, and mild cognitive impairment in adults and children. There is evolving information regarding issues with the use of...

Full description

Saved in:
Bibliographic Details
Main Authors: Donald Givler (Author), Amy Givler (Author), Patrick M. Luther (Author), Danielle M. Wenger (Author), Shahab Ahmadzadeh (Author), Sahar Shekoohi (Author), Amber N. Edinoff (Author), Bradley K. Dorius (Author), Carlo Jean Baptiste (Author), Elyse M. Cornett (Author), Adam M. Kaye (Author), Alan D. Kaye (Author)
Format: Book
Published: MDPI AG, 2023-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b34e9f6ebbbc40b88d4c827d0e513d68
042 |a dc 
100 1 0 |a Donald Givler  |e author 
700 1 0 |a Amy Givler  |e author 
700 1 0 |a Patrick M. Luther  |e author 
700 1 0 |a Danielle M. Wenger  |e author 
700 1 0 |a Shahab Ahmadzadeh  |e author 
700 1 0 |a Sahar Shekoohi  |e author 
700 1 0 |a Amber N. Edinoff  |e author 
700 1 0 |a Bradley K. Dorius  |e author 
700 1 0 |a Carlo Jean Baptiste  |e author 
700 1 0 |a Elyse M. Cornett  |e author 
700 1 0 |a Adam M. Kaye  |e author 
700 1 0 |a Alan D. Kaye  |e author 
245 0 0 |a Chronic Administration of Melatonin: Physiological and Clinical Considerations 
260 |b MDPI AG,   |c 2023-03-01T00:00:00Z. 
500 |a 10.3390/neurolint15010031 
500 |a 2035-8377 
520 |a Background: Exogenous melatonin is commonly used to treat insomnia, other sleep problems, and numerous medical illnesses, including Alzheimer's disease, autism spectrum disorder, and mild cognitive impairment in adults and children. There is evolving information regarding issues with the use of chronic melatonin. Methods: The present investigation was a narrative review. Results: Melatonin usage has risen dramatically in recent years. Many countries only allow melatonin prescriptions. In the United States (U.S.), it is classified as a dietary supplement accessible over the counter and can be derived from animals, microorganisms, or, most commonly, made synthetically. No regulatory agency oversees its manufacturing or sale in the U.S. melatonin concentration of marketed preparations varies widely between product labels and manufacturers. Melatonin's ability to induce sleep is detectable. However, it is modest for most people. Sleep length appears to be less important in sustained-release preparations. The optimal dosage is unknown, and routinely used amounts vary substantially. Melatonin's short-term negative effects are minimal, resolve at medicine cessation, and do not usually prevent usage overall. Much research on long-term melatonin administration has found no difference between exogenous melatonin and placebo in terms of long-term negative effects. Conclusion: Melatonin at low to moderate dosages (approximately 5-6 mg daily or less) appears safe. Long-term usage appears to benefit certain patient populations, such as those with autism spectrum disorder. Studies investigating potential benefits in reducing cognitive decline and increased longevity are ongoing. However, it is widely agreed that the long-term effects of taking exogenous melatonin have been insufficiently studied and warrant additional investigation. 
546 |a EN 
690 |a melatonin 
690 |a insomnia 
690 |a sleep 
690 |a aging 
690 |a dietary supplement 
690 |a autistic spectrum disorder 
690 |a Medicine 
690 |a R 
690 |a Internal medicine 
690 |a RC31-1245 
690 |a Neurosciences. Biological psychiatry. Neuropsychiatry 
690 |a RC321-571 
690 |a Neurosciences. Biological psychiatry. Neuropsychiatry 
690 |a RC321-571 
655 7 |a article  |2 local 
786 0 |n Neurology International, Vol 15, Iss 1, Pp 518-533 (2023) 
787 0 |n https://www.mdpi.com/2035-8377/15/1/31 
787 0 |n https://doaj.org/toc/2035-8377 
856 4 1 |u https://doaj.org/article/b34e9f6ebbbc40b88d4c827d0e513d68  |z Connect to this object online.